Virax Biolabs Group (Virax Biolabs Group) LT-Debt-to-Total-Asset : 0.02 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Virax Biolabs Group's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.02.

Virax Biolabs Group's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.02). It may suggest that Virax Biolabs Group is progressively becoming more dependent on debt to grow their business.

Virax Biolabs Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Virax Biolabs Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group LT-Debt-to-Total-Asset Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			-	-	-	-	0.02

Virax Biolabs Group LT-Debt-to-Total-Asset Calculation

Virax Biolabs Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0	/	9.812
	=	0.00

Virax Biolabs Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	0.132	/	7.025
	=	0.02

Virax Biolabs Group (NAS:VRAX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Virax Biolabs Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.